Articles
Latest Articles
Evidence-based analysis and clinical commentary on peptide therapeutics — updated as the literature evolves. · 19 articles
What Does the 2026 Rat Study Reveal About Semaglutide-Induced Prolonged GLP-1 Receptor Activation and Sodium Balance?
A 2026 study published in the Journal of Evolutionary Biochemistry and Physiology demonstrated for the first time that semaglutide — administered at doses of 0.125–8 nmol per 100 g body weight in rats — produces dose-dependent natriuresis through prolonged glucagon-like peptide-1 receptor (GLP-1R) activation, establishing a direct mechanistic link between sustained GLP-1R occupancy and renal sodium handling.
Does Pemvidutide Improve Alcohol Use Disorder Outcomes in Patients With Obesity — What Did the July 2026 RECLAIM Study Report?
Yes. The July 2026 RECLAIM Phase 2 trial reported that pemvidutide, a balanced GLP-1/glucagon dual receptor agonist developed by Altimmune, significantly reduced heavy drinking days and total alcohol consumption in adults with comorbid obesity and alcohol use disorder. Participants also achieved clinically meaningful weight loss, indicating simultaneous benefit across both conditions.
What Human Safety and Efficacy Data Support MOTS-c for Metabolic or Longevity Indications After the 2026 FDA Review?
As of 2026, MOTS-c lacks approved human clinical trial data for any metabolic or longevity indication. The available human evidence is limited to observational studies linking endogenous circulating MOTS-c levels to insulin sensitivity and aging phenotypes, one small exercise-intervention study, and preclinical mechanistic work. The FDA's 2026 review placed it under compounding scrutiny without an approved NDA.
What Does the FDA Panel's July 2026 Compounding Recommendation Mean for BPC-157, TB-500, and KPV When Human Efficacy Data Are Absent?
The FDA advisory panel's July 2026 vote recommended against adding BPC-157, TB-500, and KPV to the 503A bulk drug substance list, citing the absence of adequate and well-controlled human trials for all three compounds. The recommendation is non-binding but signals that compounding pharmacies cannot rely on these substances meeting the agency's clinical-need standard.
What Do 2026 Obesity Analyses Reveal About Retatrutide's Efficacy and Safety Risk-Benefit Profile?
Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist in Phase 3 development. It demonstrated up to 24.2% mean body-weight reduction at 48 weeks in its pivotal Phase 2 trial. Emerging 2026 analyses confirm robust efficacy but flag dose-dependent gastrointestinal adverse events and a persistent resting heart-rate elevation as the primary safety signals requiring ongoing risk-benefit evaluation.
Why Do GIP Receptor Agonists and Antagonists Both Produce Weight Loss in 2026 Obesity Trials?
Both GIP receptor (GIPR) agonism and antagonism reduce body weight in preclinical and early clinical models, a paradox explained by tissue-specific receptor desensitisation, differential central versus peripheral signalling, and the obligate co-presence of GLP-1 receptor activity in every trial where antagonism has shown efficacy. Neither pharmacological direction acts on GIPR in isolation.
Do GLP-1 Receptor Agonists Increase the Risk of Clinically Recorded Hair Loss Compared With Other Diabetes Drug Classes in 2026?
A 2024 BMJ target-trial emulation using Penn Medicine electronic health records found that GLP-1 receptor agonist initiators had a statistically significant higher incidence of clinically recorded alopecia than users of DPP-4 inhibitors or SGLT-2 inhibitors, with an adjusted hazard ratio of approximately 1.33 versus DPP-4 inhibitors after propensity-score weighting.